170791-09-0

• 常用中文名：三苯甲基坎地沙坦西来替昔酯
• 常用英文名：Trityl Candesartan Cilexetil
• CAS号：170791-09-0
• 分子式：C₅₂H₄₈N₆O₆
• 分子量：852.974
• 相关类别： 医药中间体 原料药中间体
• 发布时间：2018-03-05 08:00:00
• 更新时间：2026-07-09 09:59:09

名称

• 中文名: 三苯甲基坎地沙坦西来替昔酯
• 英文名: 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(1-trityltetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
• 中文别名: 1-(((环己基氧基)羰基)氧基)乙基2-乙氧基-1-((2'-(1-三丁基-1H-四唑-5-基)-[1,1'-联苯]-4-基)甲基)-1H-苯并[d]咪唑-7-羧酸盐(坎地沙坦酯杂质); (±)-1-[(环己氧基)羰基氧基]乙基 2-乙氧基-1-[[2'-(1-三苯甲基-1H-四唑-5-基)联苯-4-基]甲基]-1H-苯并咪唑-7-羧酸酯; 三苯甲基坎地沙坦西来替昔酯 中间体; 坎地沙坦酯杂质H(参见C4X-12348); 三甲基坎地沙坦酯; 坎地沙坦酯中间体C10; 坎地沙坦CILEXETIL 杂质H; 坎地沙坦酯杂质; 坎地沙坦酯中间体5; 2-乙氧基-1-[[2'-(三苯甲基-1H-四氮唑-5-基)[1,1'-联苯基]-4-基]甲基]-1H-苯并咪唑-7-甲酸-1-[[(环己氧基)羰基]氧基]乙酯; 三苯基坎地沙坦酯 C10; 三苯甲基坎地沙坦酯(坎地沙坦酯杂质); 坎地沙坦酯杂质H; 三苯甲基坎地沙坦西来替昔酯 C10; 坎地沙坦西酯杂质20; 三苯甲基坎地沙昔坦(TCDC); N1-三苯甲基坎地沙坦酯; 坎地沙坦酯中间体(C10)三苯甲基坎地沙坦西来替昔酯; 2-乙氧基-1-((2'-(1-三甲基-1H-四唑-5-基)-[1,1'-联苯]-4-基)甲基)-1H苯并[D]咪唑-7-羧酸-1-((环己基氧基)羰基氧基)乙酯; 坎地沙坦酯杂质23; 坎地沙坦酯杂质20; 2-乙氧基-1-[[2'-(三苯甲基-1H-四氮唑-5-基)[1,1'-联苯基] -4-基]甲基]-1H-苯并咪唑-7-甲酸-1-[[(环己氧基)羰基]氧基]乙酯
• 英文别名: 1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1-trityl-1H-tetrazol-5-yl)-4-biphenylyl]methyl}-1H-benzimidazole-7-carboxylate; Candestan Cilexetil Impurity H (N1-Trityl Candestan Cilexetil); 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-, hydrate (1:1); 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-cboxylate; 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 2-ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]; Triphenylmethyl candestan medoxomil; TRITYL CANDESTAN CILEXETIL; Candestan Cilexetil Intermediate; Candestan Cilexetil Impurity 8 Impurity H); Candestan Impurity H; 1-cyclohexyloxycbonyloxyethyl 2-ethoxy-3-[[4-[2-(1-trityltetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-cboxylate; Trityl candestan Methyl ester; Trityl candestan cilexetil (Candestan Cilexetil Impurity); 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester; Trityl candestan cilexetil ###METHYL 2-NITRO-1-IMIDAZOLEACETATE; ethyl 2-ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl); trityl condesartan cilexetil; (1RS)-1-[[(Cyclohexyloxy)carbonyl]oxy]ethyl 2-ethoxy-1-[[2''-[1-(triphenylmethyl)-1H-tetrazol-5-yl]biphenyl-4-yl]methyl]-1H-benzimidazole-7-cboxylate; 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 2-ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-cboxylate; TritylCandestanCilexetil[CandestanCilexetilIntermediates]; 2-ethoxy-3-[[4-[2-[1-(triphenylmethyl)-5-tetrazolyl]phenyl]phenyl]methyl]-4-benzimidazolecboxylic acid 1-[cyclohexyloxy(oxo)methoxy]ethyl ester; TRITYL CANDESTAN CILETEXITIL; UNII-006A6A2YSO; 1-(((Cyclohexyloxy); candestan cilexetil impurity1360; 2-Ethoxy-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-1H-benziMidazole-7-cboxylic Acid 1-[[(Cyclohexyloxy)carbonyl]oxy]ethyl Ester; 1-(CYCLOHEXYLOXYCBONYLOXY)ETHYL-2-ETHOXY-1-[[(2''-(1-TRIPHENYLMETHYL-1H-TETRAZOL-5-YL) BIPHENYL-4-YL)METHYL]BENZIMIDAZOLE-7-CBOXYLATE; Candestan Cilexetil N1-Trityl IMpurity ：Candestan Cilexetil N1-Trityl Analog; 1-(cyclohexyloxycbonyloxy)ethyl-2-ethoxy-1-[[(2(1-triphenylmethyl-1H-tetrazol-5-yl) biphenyl-4-yl)methyl]benzimidazole-7-cboxylate cas:(intermediate of candestan cilexetil); Trityl Candestan Cilexetil (C10); Candestan Impurity -H Candestan Cilexetil Impurity H; TriphenylMethyl candestan cilexetil; TritylCandestanEster; Candesartan Cilexetil Impurity 8; Candestan Cilexetil Impurity23; 2-Ethoxy-3-[2'-(1-trityl-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-cboxylic acid 1-cyclohexyloxycbonyloxy-ethyl ester; Candestan Cilexetil Impurity H(See C4X-12348); 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 2-ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphen; Trityl; 1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate; 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 2-ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-cboxylate (Candestan Cilexetil Impurit); UNII:006A6A2YSO; 1H-benzo[d]imidazole-7-cboxylate; Candestan Cilexetil impurity H; 1-(Benzo[b]thiophen-4-yl)piperazine hydrochloride (Intermediate of Brexpiprazole); Jikan cilexetil trityl; TRIPHENYL CANDESTAN CILEXETIL; N-Trityl Candestan Cilexetil; Candestan Impurity-H; N-Trityl Candesartan Cilexetil; 2-Ethoxy-1-[(2'-(1-trityl-1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)Methyl]-7-benziMidazolecboxylic Acid 1-(Cyclohexyloxycbonyloxy)ethyl Ester; Candestan Impurity-H / Candestan N-trityl Impurity

物化性质

• 密度: 1.3±0.1 g/cm3
• 分子式: C₅₂H₄₈N₆O₆
• 分子量: 852.974
• 精确质量: 852.363525
• PSA: 132.48000
• LogP: 12.93
• 外观性状: 白色晶体粉末
• 折射率: 1.652
• 储存条件: 2-8℃，惰性气体

安全

• 危害码 (欧洲): Xn

上下游产品

上游产品  6
139481-72-4 99464-83-2 1239349-15-5 76-83-5
145040-37-5 139481-59-7
下游产品  2
145040-37-5 869631-11-8